BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Messenger RNA technology leader BioNTech, has seen its stock rally by about 11% over the last week (five trading days) and remains up by almost 21% over the last month. This is well ahead of the S&P 500 which has returned about 2% over the last month.

Why BioNTech Stock's Rally Isn't Done Yet

Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why BioNTech SE Sponsored ADR (BNTX) is a Great Choice

BioNTech SE Sponsored ADR (BNTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why BioNTech SE Sponsored ADR (BNTX) Might be Well Poised for a Surge

Pfizer

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies' COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. The government will, in turn, donate the Pfizer-BioNTech

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations

The U.S. government plans to buy hundreds of millions more doses of the company's COVID-19 vaccine to donate to poorer countries.

Why BioNTech Blew Past the Market on Wednesday

The US will buy 500 million more doses of the Pfizer COVID-19 vaccine to share through the global COVAX alliance for donation to 92 lower-income countries and the African Union over the next year, a person familiar with the matter said Wednesday. President Joe Biden was set to make the announcement Thursday in a speech.

US to buy 500M Pfizer vaccines to share globally

The US is to distribute half a billion shots of the Pfizer vaccine to 100 other countries.

America to give 500 million COVID jabs to poorer countries

Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) will begin testing its COVID-19 vaccine in a bigger group of children under age 12 after selecting a lower dose shot in an earlier stage of the trial. The study will enroll up to 4,500 children at more than 90 clinical sites, Reuters reported.

Pfizer/BioNTech Initiates COVID-19 Vaccine Trial In Children Below 12 Years: Reuters

Germany's BioNTech has been able to boost sales by more than 7000% in the first quarter of 2021 with a better profitability metric. The biotech's vaccine which it co-developed with Pfizer has shown high efficacy against the most infectious mutant to date.

BioNTech: Long-Term Protection, Just Like For Software Antivirus On Your Laptop

Moderna

Pretty well, although it's not an apples-to-apples comparison between the two studies.

How Did Moderna's COVID Vaccine Results in Teens Stack Up Against Pfizer's?

The COVID-19 vaccine developed jointly by Pfizer and BioNTech has been approved for 12 to 15-year-olds in the U.K, the Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday. More than 2,000 children were involved in the clinical trial to determine the safety of the Pfizer-BioNTech vaccine, the chairman of the Commission on Human Medicines said.

Pfizer-BioNTech Covid-19 vaccine approved for 12 to 15-year-olds in the U.K.

It has to do with individuals who haven't yet been vaccinated.

This 1 Factor May Mean Bigger Vaccine Orders for Pfizer and Moderna

As of late, it has definitely been a great time to be an investor of BioNTech SE (BNTX).

Can the Uptrend Continue for BioNTech (BNTX)?

Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as investors see tremendous potential in leveraging mRNA technology beyond Covid, to fight a variety of.

Moderna Or BioNTech: Which mRNA Stock Should You Pick?

That spending might help him win the war on cancer.

This Biotech's Thrifty CEO Is Serious About Investing for the Future

Israel's Health Ministry has reportedly found the small number of heart inflammation cases, observed mainly in young men who received Pfizer Inc's (NYSE: PFE) COVID-19 vaccine in Israel, were likely linked to their vaccination. Pfizer said that it was aware of the Israeli observations of myocarditis and said no causal link to its vaccine had been established.

Myocarditis Cases Probably Linked to Pfizer COVID-19 Vaccine, Says Israel Health Ministry: Reuters

AstraZeneca

Dyadic International Inc., DE

Johnson & Johnson

The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have had access to a vaccine.

The Vaccine Investment Hypothesis, and What's Next (AZN, JNJ, DYAI, BNTX)

Pfizer (PFE)/BioNTech (BNTX) vaccine turns out to be 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

Pfizer (PFE) COVID-19 Vaccine Gets Nod for Adolescents in EU

NEW YORK and MAINZ, GERMANY, May 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group. The extended indication for the CMA for COMIRNATY® is valid in all 27 EU member states.

Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents

European Medical Agency backed the use of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for children as young as 12, paving the way for a broader roll-out in Europe, reports Reuters. The endorsement comes weeks after it began evaluating extending the use of the vaccine to include 12- to 15-year-olds.

European Drug Regulator Supports Use Of Pfizer-BioNTech COVID-19 Vaccine In Adolescents: Reuters

The European drugs regulator has authorized the use of the Pfizer-BioNTech COVID-19 vaccine on children aged 12 to 15, it said on Friday.

European regulator approves Pfizer-BioNTech vaccine for children 12-15

Is (BNTX) Outperforming Other Medical Stocks This Year?

Is BioNTech SE Sponsored (BNTX) Stock Outpacing Its Medical Peers This Year?

On Tuesday, Reuters reported that the EU is targeting more than 1 billion COVID-19 shots by September. This is a huge figure considering that since the vaccine roll-outs began earlier this year, only 266 million vaccinations have been administered in the European Union.

Best COVID-19 vaccine stock to buy in June: Pfizer

Many of its bets on gene-based medicine increase the odds of the next blockbuster therapy.

News for BioNTech SE Stock (BNTX)